Archives

Risk for PSE was lower for patients treated with ARBs and higher for those receiving calcium channel blockers, beta-blockers

CWI has no impact on overall survival at 10 years among patients with intermediate-risk breast cancer

Findings show survival benefits for both risk-reducing mastectomy and salpingo-oophorectomy

However, no difference seen for care guided by C-reactive protein measurement

Findings seen for four of five causes of acute respiratory failure

Omission noninferior to sentinel-lymph-node biopsy for clinically node-negative early-stage invasive breast cancer

Two-year cumulative rate of invasive ipsilateral breast cancer 5.9 and 4.2 percent for guideline-concordant care, active monitoring

Addition of camrelizumab improves pathological complete response in early or locally advanced triple negative breast cancer

Imlunestrant leads to significantly longer progression-free survival among those with ESR1 mutations, but not in overall population

Estimated disease-free survival 97.5 ± 1.3 and 90.2 ± 2.3 percent with chemotherapy plus blinatumomab, chemo alone in average-risk patients